NovelStem Provides Shareholder Update

Boca Raton, FL, May 8, 2019NovelStem International Corp. (OTC Pink: NSTM) is focused on the

substantial commercial potential of stem-cell-based diagnostic technology to aid the selection of cancer

chemotherapy agents, which technology is being developed by its 20%-owned affiliate, NewStem Ltd.

NovelStem expects to provide a shareholder update on NewStem’s progress within the next month.

NovelStem announced today that its 50% owned Netco Partners unit has executed an agreement with

Hanover Square Press, an imprint of HarperCollins, to relaunch the “Net Force” book series. Hanover

Square Press acquired publishing rights to four novels and four e-novellas in the series and anticipates the

first launch, Net Force: Dark Web, to take place in October with one novel and one e-novella expected

per year. Netco Partners received an undisclosed upfront royalty advance from Hanover Square for print

and digital rights.

Investors in a July 2018 NovelStem private placement agreed to waive their participation in distributions

“reasonably expected to exceed $500,000” generated from the Netco Partners joint venture within the first

18 months following the private placement. Reflecting the terms and timing of expected payments from

the multi-year publishing agreement, NovelStem does not expect to receive sufficient payments within the

first 18-month period to warrant a special distribution to NovelStem shareholders. All proceeds received

by NovelStem as a result of its interest in Netco Partners from the publishing agreement will benefit all

NovelStem shareholders primarily through the funding of future NewStem investments.

About NovelStem International Corp. www.novelstem.com

NovelStem has a 20% stake in NewStem Ltd. which is advancing novel stem-cell-based diagnostic

technology for predicting patients’ resistance to chemotherapy and allowing for better, targeted cancer

treatments with the potential to reduce incidents of chemotherapy resistance. NovelStem secured the right

to increase its ownership up to 33% based on the completion of up to $2 million in follow-on

contributions – at the same price - over the next 9 months. NovelStem also retains ownership stake of

50% in Netco Partners, which owns Net Force. NovelStem has 35.4 million common shares outstanding

and substantial net operating loss carry forwards.

About NewStem Ltd. NewStem Ltd. which is advancing novel stem-cell-based diagnostic technology for predicting patients’ resistance to chemotherapy, allowing for better, targeted cancer treatments with the potential to reduce

incidents of chemotherapy resistance. NewStem is a spinoff of Yissum, The Hebrew University of

Jerusalem’s technology-transfer company. NewStem’s diagnostic solutions are based on the research of

human haploid pluripotent stem cells (hHPSCs) by Professor Nissim Benvenisty of the Azrieli Center for

Stem Cells and Genetic Research. NewStem holds the intellectual property, reagents and experience

required for hHPSC isolation, differentiation, genetic manipulation, immunogenicity and tumorigenicity.

# # #

NovelStem Investor Relations

Bill Jones or David Collins – Catalyst IR

(212) 924-9800

NSTM@catalyst-ir.com

COMPANY HEADQUARTERS

2255 Glades Road, Suite 221A

Boca Raton, FL 33431

NOVELSTEM CONTACT

Phone: (410) 654-3315
Email: jloeb@leaptidecapital.com

INVESTOR RELATIONS CONTACT

William Jones: (267) 987-2082
David Collins: (212) 924-9800

Email: nstm@catalyst-ir.com